
Pancreatic Cancer Drug
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
Vidcast: https://www.instagram.com/p/DPa20mdDoub/
University of Cincinnati oncologists have developed a drug that stops pancreatic cancer from suppressing the anti-tumor immunity that threatens to eradicate it. Using a pre-clinical mouse pancreatic cancer model, the researchers pinpointed that the protein Hsp70 is produced by the cancer cells to defuse the anti-cancer immune response.
Their next step was to find an antidote Hp70. That they did by developing the rescue agent SapC-DOPG. This drug adheres to pancreatic cancer cells, inhibits Hsp70, and destroys the tumor’s shield against killer T lymphocytes.
The next step is to bring this rescue compound and others like it into the clinic for an array of trials. Hopefully, they will confirm the effectiveness of this concept and join the fight against this dread disease…..someday soon.
#pancreatic #cancer #immunotherapy #hsp70 #sapCDOPG
pancreatic, cancer, immunotherapy, hsp70, sapCDOP